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Abstract
Purpose Data from two randomized trials, evaluating a
single-day regimen of palonosetron plus dexamethasone
against emesis due to moderately emetogenic chemotherapy,
were assessed for the impact of age on outcome in a pooled
sample of women receiving anthracycline and/or cyclophos-
phamide (AC)-containing chemotherapy.
Methods Chemo-naïve breast cancer patients randomized to
receive palonosetron (0.25 mg) plus dexamethasone (8 mg
IV) on day 1 of chemotherapy (n0200), or the same regimen
followed by oral dexamethasone (8 mg) on days 2 and 3 (n0
205), were included in the analysis. The primary endpoint was
complete response (CR: no vomiting and no rescue anti-
emetics) in the 5-day study period. The effect of the 1-day
regimen and age (<50 and ≥50 years) was investigated by a
meta-analysis of individual patient data.
Results Younger patients comprised 43 % and 49 % of the 1-
day and 3-day regimen groups, respectively; 94 % of the
pooled sample received the AC combination. There were no
between-treatment differences in CR rate according to age
during all observation periods. In the 1-day regimen group,
55.2 % of younger patients achieved overall CR compared
with 54 % of older patients. In the 3-day regimen group,
51.5 % of younger patients achieved overall CR compared
with 58.7 % of older patients. In the adjusted analysis, youn-
ger age was not associated with overall CR to treatment (risk
difference, −3.1 %; 95 % CI, −13.0 to 6.7 %; P00.533).
Conclusions These results provide evidence that, irrespective
of age, the dexamethasone-sparing regimen is not associated
with a significant loss in overall anti-emetic protection in
women undergoing AC-containing chemotherapy.
Keywords Palonosetron . Dexamethasone . CINV . Breast
cancer . AC-containing chemotherapy . Meta-analysis
Introduction
Chemotherapy-induced nausea and vomiting (CINV)
remains one of the most distressing side effects of
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cancer chemotherapy, in part because both treatment-
related and patient-related risk factors need to be con-
sidered to ensure optimal CINV control for individual
patients. The strongest of patient-related factors are gen-
erally assumed to be gender and age. Women have an
increased risk of CINV, and patients less than 50 years
old are also more likely than older patients to suffer
from CINV [1]. Both female gender and younger age
affect the intrinsic emetogenicity of the chemotherapy
regimen that has been described as the most important
risk factor for CINV [2]. Although agents such as
cyclophosphamide and anthracyclines (doxorubicin and
epirubicin) are individually considered as being moder-
ately emetogenic, combinations of emetogenic agents
may have additive effects on the overall emetogenicity
of a regimen [2]. It has been recognized that women
receiving the combination of an anthracycline and cy-
clophosphamide (AC) are at a particularly high risk of
nausea and vomiting [3, 4].
The second-generation serotonin (5-HT3)-receptor an-
tagonist palonosetron is the only agent in the class that
was approved by the Food and Drug Administration for
use in preventing delayed nausea and vomiting after
single-day administration of moderately emetogenic che-
motherapy (MEC) [5]. In a recently reported double-
blind, randomized phase III trial in patients undergoing
either cisplatin or AC-containing chemotherapy, palono-
setron plus dexamethasone for 3 days provided com-
plete protection against delayed CINV that was
superior to a single-dose of granisetron plus 3-day dexa-
methasone [6]. However, dexamethasone for prophylaxis
of delayed emesis after MEC induces moderate-to-
severe adverse effects that may have a substantial im-
pact on the quality of life [7]. There is also an interest
in reducing the dose of dexamethasone in certain clin-
ical situations and/or in subsets of patients [8]. More
recently, two similarly designed randomized phase III
trials have evaluated the efficacy of a dexamethasone-
sparing regimen for prevention of acute and delayed
CINV due to single-day MEC regimens [9, 10]. In
one trial, the patient population consisted of women
with breast cancer undergoing AC-containing chemo-
therapy, while patients with solid tumors undergoing a
broad range of MEC regimens were enrolled into the
second trial. In both studies, palonosetron plus a single-
dose of dexamethasone provided complete protection
against CINV (primary endpoint) which was non-inferior to
that of palonosetron plus 3-day dexamethasone in the overall
5-day study period.
The purpose of this retrospective post hoc analysis was to
assess the impact of age on prevention of CINV in the pooled
data set of women with breast cancer undergoing anthracy-
cline and/or cyclophosphamide-containing chemotherapy.
Patients and methods
Study design
A pre-specified retrospective analysis was conducted using
individual patient data from women with breast cancer re-
ceiving specific chemotherapy regimens who were enrolled
in two multicenter, randomized, phase III, comparative tri-
als. Both studies tested the non-inferiority of a single-day
regimen of palonosetron and dexamethasone, compared
with the same regimen on day 1 followed by dexamethasone
on days 2 and 3, for the prevention of acute and delayed
CINV after the first cycle of chemotherapy. Detailed
descriptions of the design (including eligibility criteria)
and primary efficacy and tolerability results of these studies
have been reported elsewhere [9, 10]. Both studies had local
institutional review board approval and written informed
consent was obtained when patients entered each individual
trial.
Patients and treatment
Chemo-naïve women, aged ≥18 years old with histological-
ly confirmed breast cancer, scheduled to receive a single
dose of intravenous anthracycline (doxorubicin ≤60 mg/m2
or epirubicin ≤100 mg/m2) and/or cyclophosphamide
(<1,500 mg/m2 on day 1), were eligible for enrolment.
Additional chemotherapeutic agents of Hesketh emetogenic
level 2 or lower could be added to the above regimens [2].
All patients had an adequate Eastern Cooperative Oncology
Group (ECOG) performance status of 0, 1, or 2. In both
studies, regardless of assignment to either study arm, all
patients received a single intravenous dose of palonosetron
(0.25 mg) as a bolus given 30 min before initiation of
chemotherapy on day 1. Administration of prophylactic
dexamethasone (8 mg intravenously) before the initiation
of chemotherapy on day 1 was also required. Patients were
randomly assigned to receive one of two delayed anti-emetic
regimens: no additional treatment (1-day regimen) or dexa-
methasone (8 mg orally) on days 2 and 3 (3-day regimen).
After chemotherapy, rescue medication for treatment of
nausea and vomiting was permitted on an as-needed basis.
Assessments
Patients made daily entries in their diary for 5 days after
starting chemotherapy to record emetic events and severity
of nausea in the previous 24 h, as well as any use of rescue
medication. The primary efficacy endpoint of both studies
was the proportion of patients with complete response (CR;
defined as no emetic episodes and no rescue anti-emetics)
during the overall 5-day study period after the first cycle of
chemotherapy.
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A modified intention-to-treat analysis was conducted,
including all women who received chemotherapy, took the
study medication, and completed the follow-up period
(days 1–5 following the initiation of chemotherapy). The
post hoc analysis was conducted on the pre-specified end-
point of CR during the overall 5-day study period. The
impact of the 1-day regimen on CR and on age as a pre-
specified baseline risk factor (<50 years, ≥50 years) for
CINV was investigated [1]. Treatment effects were also
estimated within each age category for the acute (0–24 h)
and the delayed (24–120 h) time periods. Secondary effica-
cy endpoints of no vomiting and no nausea were also
assessed.
Statistical analysis
Individual patient data for randomly assigned women
with breast cancer undergoing specific chemotherapy
regimens were included in the pooled analysis. A
meta-analysis of individual patient data was performed
using the CR in the overall 5-day study period as
dependent variable [11]. A generalized mixed linear
model with study and treatment group as dummy-fixed
effect was implemented with binomial distribution, iden-
tity link function (non-canonical link function) and het-
erogeneity (non constant) within study variance. The
treatment-by-study interaction was planned to be added
to the original model (fixed-effect meta-analysis) as an
additional random effect in order to investigate and
adjust estimates for the heterogeneity across studies
(random-effect meta-analysis). The treatment-by-study
interaction was considered statistically significant if the
P value was ≤0.10. Since the random-effect model did
not converge, the between-group difference with its
associated 95 % confidence interval (CI) was estimated
using only the fixed-effect model. The effect of age on
treatment outcome was evaluated using an extension of
the original model with age as a subject-level covariate.
Results were reported as risk differences (RDs) that
allowed a straightforward comparison between the two-
sided 95 % CI of the between-group difference in CR
to anti-emetic treatment for testing the non-inferiority
hypothesis of the 1-day regimen (preset threshold of
a −15 % difference between groups in both original
studies) [9, 10].
Fisher’s exact test was used to compare proportions of
the other categorical variables. These secondary analyses
were evaluated in an explorative or descriptive manner,
and therefore no adjustment for multiplicity was applied.
All P values were two-sided, and a P<0.05 was considered
statistically significant. All statistical analyses were per-




Of the 632 patients from the intention-to-treat populations in
the two clinical studies, all randomly assigned 405 women
(64.1 %) with breast cancer undergoing anthracycline and/or
cyclophosphamide-containing chemotherapy were evaluable
and included in the analysis. Among the evaluable patients,
188 (46.4 %) were younger than 50 years (43.5 % in 1-day
regimen and 49.3 % in 3-day regimen). Patient demographic
and baseline characteristics were similar between the
dexamethasone-sparing and comparator groups (Table 1).
The mean age for the pooled sample was 51 years (range, 26
to 78 years), and the vast majority of the study population
(78.5 %) had a history of light or no alcohol consumption.
Ninety-four percent of the pooled sample received a combi-
nation of AC for their chemotherapy regimen.
Primary outcome
The proportion of patients in the individual studies and
pooled sample achieving CR during all time periods is
Table 1 Baseline characteristics of the pooled population by treatment
group










Standard deviation 10.5 10.5
Race, white 100 100
Primary tumor, breast 100 100
ECOG PS 0-1 100 100










Palo plus dex palonosetron plus dexamethasone, ECOG PS Eastern
Cooperative Oncology Group performance status, AC anthracycline
(doxorubicin or epirubicin) plus cyclophosphamide, CMF cyclophos-
phamide plus methotrexate plus fluorouracil
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presented in Table 2. The CR data from the individual
studies showed that the direction of the treatment effect
was similar between treatment groups during the acute,
delayed, and overall time periods. In the pooled analysis,
the overall CR rate was 54.5 % (95 % CI, 47.3 % to 61.5 %)
in patients receiving the 1-day regimen and 55.1 % (95 %
CI, 48 % to 62.1 %) in those receiving the 3-day regimen,
with a between-treatment RD of −0.5 % (95 % CI, −10.3 %
to 9.3 %). Therefore, the non-inferiority hypothesis of the 1-
day regimen was confirmed, as the lower boundary of the
95 % CI of the RD with the 3-day regimen was greater than
the preset threshold of −15 % difference.
Figure 1 shows the proportion of patients with CR in all
three observation periods, by age and treatment group. There
were no statistically significant between-treatment differences
in CR rate according to the age categories during all three time
periods. For the overall time period, no incremental improve-
ment was observed with additional dexamethasone doses (i.e.,
the between-treatment difference) in the subgroup of younger
patients, while the improvement was of only small magnitude
(approximately 5 %) in the subgroup of older patients. As
expected, the incremental improvement observed with addi-
tional dexamethasone doses was also of greater magnitude
among older patients (10 %) compared with that seen among
younger patients (3 %) in the delayed time period.
The first-order interaction of overall CR between anti-
emetic treatment and age was not statistically significant,
providing no evidence for a differential treatment benefit on
overall CR by age. In the adjusted analysis, age was not
associated with worse outcome in terms of overall CR to
anti-emetic treatment (<50 vs. ≥50 years: RD −3.1 %; 95 %
CI, −13.0 to 6.7 %; P00.533). Since the lower boundary of
the 95 % CI for the RD from the 3-day regimen was greater
than the preset threshold of −15 % difference (1-day vs. 3-
day: RD −0.7 %; 95 % CI, −10.6 to 9.1 %), the non-
inferiority hypothesis of the 1-day regimen was also dem-
onstrated after adjusting for age.
Secondary outcomes
Subset analyses of each treatment group by age were done
for the secondary efficacy endpoints during all three obser-
vation periods (Table 3). In the pooled sample, across both
treatment groups and at all time periods, the proportion of
patients with no vomiting was high (>70%), and there was
no evidence of a differential treatment-group benefit. How-
ever, in the delayed time period, 12 % lower vomiting
control was observed among older patients following the
1-day regimen, when compared with older ones following
the 3-day regimen (77 % vs. 89.4 %; P00.018).
The proportion of patients with no nausea in either treat-
ment group was similar for both the pooled sample and the
subgroup of younger patients at any time period, while there
was a trend toward improved control of nausea in older
patients following the 3-day regimen compared with those
following the 1-day regimen in the delayed and overall time
periods (delayed, 41.6 % vs. 53.8 %; P00.078; overall,
32.7 % vs. 46.1 %; P00.052).
Table 2 Complete response (defined as no emetic episodes and no rescue anti-emetics) rates in all time periods by individual studies and treatment
group
Complete responses
Palo plus 1-day Dex, n/N (%) Palo plus 3-day Dex, n/N (%) aRisk difference between groups (95 % CI), %
Acute phase (0–24 h)
Aapro et al. [9] 105/151 (69.5) 102/149 (68.5) 1.1 (−9.4, 11.6)
Celio et al. [10] 40/49 (81.6) 40/56 (71.4) 10.2 (−6.0, 26.4)
All 145/200 (72.5) 142/205 (69.3) 3.8 (−5.1, 12.7)
Delayed phase (24–120 h)
Aapro et al. 94/151 (62.3) 98/149 (65.8) −3.5 (−14.4, 7.4)
Celio et al. 29/49 (59.2) 42/56 (75) −15.8 (−33.9, 2.2)
All 123/200 (61.5) 140/205 (68.3) −6.8 (−16.2, 2.5)
Overall phase (0–120 h)
Aapro et al. 81/151 (53.6) 80/149 (53.7) 0.0 (−11.4, 11.3)
Celio et al. 28/49 (57.1) 33/56 (58.9) −1.8 (−20.9, 17.4)
All 109/200 (54.5) 113/205 (55.1) −0.5 (−10.3, 9.3)b
Palo plus dex palonosetron plus dexamethasone, n number of complete responses, N number of patients, CI confidence interval
a One-day minus 3-day regimen with 95 % CI obtained using individual patient meta-analysis for the overall study cohort
b Non-inferiority hypothesis in primary analysis was demonstrated as the lower boundary of the 95 % CI of risk difference greater than the preset
threshold (−15 %)
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Figure 2 shows the frequency of no vomiting and no
nausea during the 5 days post-chemotherapy, by age and
treatment group. Among the younger patients in each treat-
ment group, a trend for higher control of vomiting and
nausea was maintained with a clear increase of protection
from days 1 to 5. The rates of no vomiting or no nausea
were higher among older patients in both treatment groups,
but CINV control reached a plateau between days 2 and 3 in
patients receiving dexamethasone only on day 1. Signifi-
cantly lower rates of older patients following the 1-day
regimen were free of vomiting on days 2 and 3 compared
with those following the 3-day regimen (day 2, 84.9 % vs.
96.2 %; P00.006; day 3, 86.7 % vs. 99.0 %; P00.0004).
Similarly, the proportion of older patients free of nausea was
lower in the 1-day treatment group than in the 3-day treat-
ment group over the 5 days post-chemotherapy, with the
differences reaching statistical significance on day 3 (55.8 %
vs. 73.1 %; P00.011).
Discussion
An approach based upon not only the emetogenicity of
chemotherapy but also known risk factors would be desir-
able to tailor the anti-emetic regimen to individual patients.
We assessed pooled data from two phase III studies to
investigate the potential effect of age on outcome of a
dexamethasone-sparing regimen in women with breast can-
cer undergoing a highly emetogenic AC combination [9,
10]. The retrospective post hoc analysis described here
yielded two key findings: (1) the non-inferiority hypothesis
of palonosetron plus single-dose dexamethasone could be
confirmed in an adjusted model studying the influence of
age and (2) an age younger than 50 years was not an
independent predictor for poorer outcome in terms of overall
CR to anti-emetic treatment.
The finding that the non-inferiority of the 1-day regimen
was confirmed even after adjustment for age is of particular
interest as it was obtained in a homogeneous cohort of
female patients receiving a very uniform emetogenic stimu-
lus, and further demonstrates the clinical value of palonose-
tron plus single-dose dexamethasone in this high-risk
population [9].
Another key finding of this study is that an age less than
50 years was not significantly associated with overall CR to
anti-emetic treatment in an adjusted analysis. In spite of the
relatively small sample size, the more likely explanation for
this finding is that age was an unimportant predictor in this
analysis because of the modest impact of additional dexa-
methasone doses on treatment outcome in this cohort of
patients. In an exploratory analysis, inclusion of dexameth-
asone on days 2 and 3 after the initiation of chemotherapy
revealed a different emetic risk profile between the age
subgroups in the delayed time period. Among younger
patients, both vomiting and nausea control rates were sim-
ilar between treatment groups with a clear increase of pro-
tection from days 1 to 5. This finding suggests that the
unique mechanism of action for palonosetron may at least
in part neutralize the impact of additional dexamethasone in
this subgroup at potentially higher risk. It is also interesting
to observe that inter-individual variations concerning the
metabolism of endogenous cortisol have been reported to
contribute to the individual risk profile for CINV [12]. In
addition, in ovarian cancer patients receiving cisplatin-based
chemotherapy dexamethasone added to the anti-emetic ef-
fect of ondansetron primarily in women with lower basal
urinary excretion of cortisol [13]. Since younger individuals
Fig. 1 Proportion of patients with complete response (no emesis, and
no rescue anti-emetics) in the acute, delayed, and overall time periods,
by age and treatment group. a Patients younger than 50 years. b
Patients 50 years or older. palo plus dex palonosetron plus dexameth-
asone. P values calculated by two-sided Fisher’s exact test (1-day vs.
3-day)
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tend to have lower cortisol levels than older subjects [14],
we speculate that differences in endogenous cortisol secre-
tion can partly explain the age variations in risk for CINV.
Therefore, our findings in the subgroup of younger patients
probably reflect the very modest impact of additional dexa-
methasone doses on anti-emetic control in individuals who
generally have low total exposure to endogenous cortisol.
As expected, for the delayed time interval, there were lower
control rates of both vomiting and nausea among older
patients receiving single-dose dexamethasone, when com-
pared with older patients receiving dexamethasone for
3 days. In the face of age-related increases in total exposure
to endogenous cortisol, we suggest that further improvement
in control of delayed CINV in older patients following the 3-
day regimen may be likely due to the effect of additional
dexamethasone doses primarily in old women with relative-
ly lower cortisol levels. Clinical investigations addressing
relationship between patient’s corticosteroid milieu and anti-
emetic efficacy of dexamethasone in patients undergoing
emetogenic chemotherapy should be conducted to substan-
tiate these hypotheses.
It should be kept in mind that approximately 40 % of
women with breast cancer is over the age of 65 years [15],
and the increased age generally puts them in a lower risk
category for CINV [1]. However, older patients warrant par-
ticular attention in the selection of an anti-emetic regimen
because older age is associated with decreased drug metabo-
lism and clearance and increased co-morbidity which, coupled
with increased frequency of poly-pharmacy, greatly increases
the risk of unwanted drug interactions [16]. In spite of the
potential for lower control rates of delayed symptoms among
older patients receiving 1-day dexamethasone dosing, several
observations indicate that our results may support clinicians
who desire to tailor the therapy in these patients by reducing
the overall exposure to dexamethasone. In the exploratory
evaluation of daily occurrence of symptoms, the rates of older
Table 3 Results of pooled analysis of no vomiting and no nausea for all time periods, by age and treatment group
Palo plus 1-day Dex, n/N (%) Palo plus 3-day Dex, n/N (%) aRisk difference between groups (95 % CI), %
No vomiting
Acute phase (0–24 h)
All 164/200 (82) 162/205 (79) 3.0 (−4.7, 10.7)
<50 years 67/87 (77) 70/101 (69.3) 7.7 (−5.0, 20.4)
≥50 years 97/113 (85.8) 92/104 (88.5) −2.6 (−11.5, 6.3)
Delayed phase (24–120 h)
All 161/200 (80.5) 177/205 (86.3) −5.8 (−13.1, 1.4)
<50 years 74/87 (85.1) 84/101 (83.2) 1.9 (−8.6, 12.4)
≥50 years 87/113 (77) 93/104 (89.4) −12.4 (−22.4, 2.4)*
Overall phase (0–120 h)
All 144/200 (72) 149/205 (72.7) −0.7 (−9.4, 8.0)
<50 years 61/87 (70.1) 65/101 (64.4) 5.7 (−7.7, 19.2)
≥50 years 83/113 (73.5) 84/104 (80.8) −7.3 (−18.5, 3.9)
No nausea
Acute phase (0–24 h)
All 103/200 (51.5) 103/205 (50.2) 1.3 (−8.5, 11.0)
<50 years 38/87 (43.7) 39/101 (38.6) 5.1 (−9.0, 19.2)
≥50 years 65/113 (57.5) 64/104 (61.5) −4.0 (−17.1, 9.1)
Delayed phase (24–120 h)
All 80/200 (40) 95/205 (46.3) −6.3 (−15.9, 3.3)
<50 years 33/87 (37.9) 39/101 (38.6) −0.7 (−14.6, 13.3)
≥50 years 47/113 (41.6) 56/104 (53.8) −12.2 (−25.6, 1.0)
Overall phase (0–120 h)
All 63/200 (31.5) 74/205 (36.1) −4.6 (−13.8, 4.6)
<50 years 26/87 (29.9) 26/101 (25.7) 4.1 (−8.7, 16.9)
≥50 years 37/113 (32.7) 48/104 (46.1) −13.4 (−24.4, 0.4)
Palo plus dex palonosetron plus dexamethasone, n number of responders, N number of patients, CI confidence interval
a One-day minus 3-day regimen with 95 % CI obtained from the individual patient meta-analysis
*P00.018 (two-sided Fisher’s exact test [1-day vs. 3-day])
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patients with no vomiting or no nausea receiving palonosetron
plus single-dose dexamethasone were high (≥85% for vomit-
ing control and >55% for nausea control) andmaintained from
days 1 to 5, suggesting that it is difficult to accurately evaluate
the clinical impact of the differences compared with older
patients receiving the 3-day regimen. In spite of the intrinsic
limitations of inter-study comparisons, a post hoc analysis of a
large phase III trial in a similar population of breast cancer
patients undergoing AC-containing chemotherapy random-
ized to either a triple regimen, including the NK-1 receptor
Fig. 2 Frequency of no vomiting and no nausea during the 5-day
period after chemotherapy, by age and treatment group. a Overall
population. b Patients younger than 50 years. c Patients 50 years or
older. palo plus dex palonosetron plus dexamethasone. *P00.006
(two-sided Fisher’s exact test [1-day vs. 3-day]). **P00.006; ***P0
0.0004; #P00.011
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antagonist aprepitant, or a control regimen (single-dose dexa-
methasone plus 3-day ondansetron), appears to support this
interpretation [17]. Although no data concerning the incidence
of no nausea were available for the aprepitant study, when
compared with the efficacy results of the triple regimen by age
the overall proportion of older patients with no vomiting in the
palonosetron and 1-day dexamethasone group was consistent
with that seen among older patients (≥55 years) receiving
aprepitant for 3 days (73 % vs. 79 %). Likewise, the overall
proportion of younger patients with no vomiting in the pal-
onosetron and 1-day dexamethasone group was consistent
with the results observed among younger patients
(<55 years) receiving aprepitant for 3 days (70 % vs. 73 %).
It also should be noted that optimal nausea control remains an
unmeet need in CINV research and the NK-1 receptor antag-
onists have not been shown to be effective in improving
nausea control in patients receiving AC-containing chemo-
therapy [8, 18].
Current guidelines recommend a triple regimen consisting
of a 5-HT3-receptor antagonist plus dexamethasone and an
NK-1 receptor antagonist for the prevention of CINV due to
the combination of AC [3, 4, 19]. However, if an NK-1
antagonist is not available, women undergoing AC-
containing chemotherapy should receive palonosetron plus
3-day dexamethasone [3]. Our findings indicate that, irrespec-
tive of age, the 1-day regimen offers high and similar overall
control of symptoms as the 3-day regimen in this population.
One limitation of this analysis is that we were unable to
assess the impact of age in an adjusted model including
terms for other possible risk factors for CINV in breast
cancer patients [17, 20]. Very few patients in the pooled
sample consumed alcohol regularly, while no data were
collected on other risk factors in the individual trials. A
second limitation of our study is that all patients had early-
stage disease and an excellent performance status. However,
since AC-containing regimens are the mainstay of adjuvant
chemotherapy for breast cancer and the majority of patients
undergo adjuvant therapy, the present findings should have
widespread applicability.
This post hoc analysis confirms the non-inferiority of
palonosetron plus single-dose dexamethasone for the
prevention of CINV associated with the highly emeto-
genic combination of AC in breast cancer patients, even
after adjusting for the influence of age. The current
findings also indicate that younger age does not predict
decreased efficacy in terms of overall CR to the
dexamethasone-sparing regimen. Therefore, it is reason-
able to conclude that tailoring dexamethasone dosing to
reduce exposure in women treated with palonosetron on
day 1 is not associated with a clinically significant loss
in anti-emetic protection during the 5-day observation
period. Since a triple regimen including aprepitant is the
guideline-recommended treatment in the setting of AC-
containing chemotherapy and no randomized data about
palonosetron plus aprepitant are still available, addition-
al randomized studies of the dexamethasone-sparing
regimen with or without aprepitant to separate the
anti-emetic effects of palonosetron and aprepitant are
needed to validate this interesting observation. Although
some older women receiving dexamethasone for 3 days
may experience improved control of delayed CINV, the
potential additional benefit of taking dexamethasone for
3 days in older patients needs to be weighed against the
increased risk for drug–drug interactions and problems
with compliance in multiple-dosing regimens. Our find-
ings may be also of help to clinicians who strive to
reduce the total dexamethasone dose administered in
patients who have relative contraindications against the
use of corticosteroids.
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